STRATA Skin Sciences (SSKN) announced that the Centers for Medicare & Medicaid Services, CMS, has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued reimbursement for excimer laser treatments under CPT codes 96920, 96921, and 96922, while recognizing the upcoming expansion of CPT code descriptors to include inflammatory and autoimmune skin conditions beyond psoriasis-effective January 1, 2027. In the Final Rule, CMS recognized the excimer laser as a well-established treatment modality, affirmed continued coverage as well as increase in payment for calendar year 2026, and indicated it will review extensive clinical and real-world cost data submitted by STRATA and other stakeholders as part of CY 2027 rulemaking alongside the American Medical Association CPT Editorial Panel revisions and the RUC’s recommendations. The final rule confirms that at-least until the CPT code language changes take effect on January 1, 2027, the current code family remains exclusive to excimer laser technology.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- Strata Skin Sciences announces COFEPRIS clearance of TheraClear in Mexico
- Strata Skin Sciences provides update on positioning, litigation
- Strata Skin Sciences Announces Equity Distribution Agreement
- Strata Skin Sciences Granted Nasdaq Compliance Extension
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
